Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Recap

Ironwood's shares gained 4.1% following a strong LINZESS performance that drove raised full-year guidance, supported by both demand growth and improved pricing, while advancing apraglutide development and maintaining solid profitability.

Key Takeaways

• LINZESS U.S. net sales reached $282.3 million in Q2, up 14% year-over-year, powered by mid-single-digit prescription demand growth and improved net pricing.
• First half LINZESS net sales totaled $555 million, a 44% increase year-over-year, contributing to raised full-year 2026 financial guidance.
• The FDA approved LINZESS for pediatric functional constipation, extending the drug’s market exclusivity and addressing new patient segments.
• Apraglutide Phase III STARS-2 trial officially initiated, with patient recruitment underway to confirm earlier positive data.
• Q2 financials included $51.3 million GAAP net income and $83 million adjusted EBITDA, with repayment of $200 million convertible notes, positioning the company for further debt reduction and sustained cash flow generation.